Clinical trial · Other
A Study of Lotiglipron in Participants With Type 2 Diabetes
Pfizer-lotiglipron-Ph2
Trial identity
- Registry
- Other
- Registry ID
- Pfizer-lotiglipron-Ph2
- Phase
- Phase 2
- Design
- Interventional
- Allocation
- Randomized
- Masking
- Double-blind
- Overall status
- Terminated
- Result status
- none
Sponsors & collaborators
- Sponsor
- Pfizer
- Collaborators
- —
Intervention assets
Arms
| Arm | Intervention | Enrollment |
|---|---|---|
| Lotiglipron QD | lotiglipron once daily | — |
| Placebo | placebo once daily | — |
Population & enrollment
- Population summary
- Adults with type 2 diabetes.
- Eligibility summary
- HbA1c 7.0-10.5%, BMI ≥25 kg/m².
- Planned enrollment
- 250
- Actual enrollment
- 200
Endpoints
- Primary endpoint
Change in HbA1c from baseline
- Secondary endpoints
Body weight change
Safety and tolerability
Dates
- Start date
- Aug 15, 2022
- Primary completion
- Jun 26, 2023
- Completion date
- Jun 26, 2023
- Last synced
- Aug 15, 2024
Locations
- United States
Changes
- Trial terminated following Pfizer discontinuation announcement on 2023-06-26.
Plain-language interpretation
A Study of Lotiglipron in Participants With Type 2 Diabetes is a Phase 2 Interventional sponsored by Pfizer. It is evaluating Lotiglipron in Adults with type 2 diabetes.. The primary endpoint is Change in HbA1c from baseline.
Registry disclaimer: Information is derived from public registry records and may lag behind the official source. Always verify against Other.